John Fanikos Shares Greg Piazza’s Presentation On The Results of The HI-Pro Trial
John Fanikos, Director of Strategic Initiatives at North American Thrombosis Forum, shared on LinkedIn:
”The best part of my pharmacist career was spending time with the Thrombosis Research Group.
Dr. Greg Piazza presented the results of the HI-Pro Trial at the European Society Meeting over the Labor Day weekend in Madrid, Spain.
There are often reasons (surgery, infection, injury) patients developed blood clots (deep vein thrombosis and pulmonary embolism) in their legs and lungs.
These events were called “provoked” and treated with medicines (anticoagulants) for 3-6 months.
Dr. Piazza’s research suggests treating longer, and with a lower dose, may prevent repeat events and be better for patients.
Kudos to the research group. Kudos to the Investigational Drug Service Pharmacy (IDS) that delivered the drugs by foot, by FedEx, and by UPS in the peri-pandemic period to keep patients on their medications.
I was honored to be included.”
Stay updated on the latest news in the field of thrombosis with Hemostasis Today.
-
Sep 10, 2026, 14:39Piotr Czempik: ROTEM Guided Anticoagulation in Severe Thrombocytopenia and Acute VTE
-
Sep 10, 2026, 14:30Adil Aftab: Acute VTE Treatment and Anticoagulation Considerations in Renal Dysfunction
-
Sep 10, 2026, 14:21Seth Green: Testosterone Replacement Therapy and VTE Risk When Is the Risk Highest
-
Sep 10, 2026, 13:56Sumyea Kabir: Wet Hijama and Blood Donation Why Deferral Matters
-
Sep 10, 2026, 11:56William Pao: Celebrating a Landmark Breakthrough in Hemophilia Care
-
Sep 10, 2026, 11:25Andreas Glenthøj: New Sickle Cell Trait Data in UpToDate
-
Sep 10, 2026, 10:53A New Era of Hemophilia Screening and Diagnosis in Women and Girls – ISTH
-
Sep 10, 2026, 10:03Investing in Youth, Transforming Hemophilia Care – WFH
-
Sep 10, 2026, 09:51Ronke Oke BEM: 20 Years of Newborn Sickle Cell Screening in England